In this large retrospective cohort of >32,000 patients with 4 common diagnoses with moderate to high risk of VTE, about half received LMWH and half UFH. There were no differences between the groups in rates of VTE, bleeding or cost, but UFH was associated 2.8 times the odds of a complication requiring discontinuation compared to LMWH. This large systematic review found LMWH was associated with lower odds of complications compared to UFH (abstract)
Share This Post
Categories
Related Posts
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment